Across TCGA pan-cancer cohorts, UPK3A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UPK3A data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher UPK3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UPK3A expression acts as an unfavorable survival marker.
CESC, BLCA, and ACC are the cancer types where UPK3A Mutation most reproducibly stratifies survival.